Literature DB >> 12889515

Tamoxifen inhibits arylamine N-acetyltransferase activity and DNA-2-aminofluorene adduct in human leukemia HL-60 cells.

K H Lu1, K L Lin, T C Hsia, C F Hung, M C Chou, Y M Hsiao, J G Chung.   

Abstract

Genetic regulation of acetyl coenzyme A-dependent N-acetyltransferase (NAT)and O-acetyltransferase (OAT) activities may play an important role in the metabolic activation of arylamine chemicals and carcinogens. N-acetylation is thought to be the first step in arylamine metabolism. The enzyme responsible for N-acetylation is called NAT. In this study, synthetic non-steroidal antiestrogen tamoxifen was selected for determining the inhibition of arylamine NAT activity, gene expression (NAT mRNA) and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cell line. The results demonstrated that tamoxifen did not affect the level of NAT mRNA in HL-60 cells. But the results also showed that NAT activity and 2-Aminofluorene-DNA adduct formation in HL-60 cells were inhibited and decreased by tamoxifen in a dose-dependent manner when the doses of tamoxifen up to 100 micro M. We also examined the standard steady-state kinetic analysis, and the data showed that tamoxifen may be an uncompetitive inhibitor to NAT activity in cytosols based on the decrease apparent values of Km and Vmax. This report is the first finding that tamoxifen inhibited human leukemia HL-60 cells NAT activity and DNA-2-aminofluorene on adduct formation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12889515

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  5 in total

1.  Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.

Authors:  Xin Hu; Emmanuel Martinez-Ledesma; Siyuan Zheng; Hoon Kim; Floris Barthel; Tao Jiang; Kenneth R Hess; Roel G W Verhaak
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

Review 2.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

3.  Prospective virtual screening with Ultrafast Shape Recognition: the identification of novel inhibitors of arylamine N-acetyltransferases.

Authors:  Pedro J Ballester; Isaac Westwood; Nicola Laurieri; Edith Sim; W Graham Richards
Journal:  J R Soc Interface       Date:  2009-07-08       Impact factor: 4.118

4.  Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1.

Authors:  Akane Kawamura; Isaac Westwood; Larissa Wakefield; Hilary Long; Naixia Zhang; Kylie Walters; Christina Redfield; Edith Sim
Journal:  Biochem Pharmacol       Date:  2008-01-05       Impact factor: 5.858

Review 5.  Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.

Authors:  E Sim; A Abuhammad; A Ryan
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.